The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957.

ABSTRACT: New antimalarial therapeutics are needed to ensure that malaria cases continue to be driven down, as both emerging parasite resistance to frontline chemotherapies and mosquito resistance to current insecticides threaten control programmes. Plasmodium, the apicomplexan parasite responsible for malaria, causes disease pathology through repeated cycles of invasion and replication within host erythrocytes (the asexual cycle). Antimalarial drugs primarily target this cycle, seeking to reduce parasite burden within the host as fast as possible and to supress recrudescence for as long as possible. Intense phenotypic drug screening efforts have identified a number of promising new antimalarial molecules. Particularly important is the identification of compounds with new modes of action within the

SUBMITTER: Miguel-Blanco C 

PROVIDER: S-EPMC7820608 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature